Foghorn announces Lilly selects FHD-909 for clinical development; IND planned for Q2 2024

Foghorn Therapeutics Inc.

Lilly selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development.
Lilly plans to file an IND for FHD-909 in Q2 2024 for BRG1 mutated NSCLC.
FHD-909 targets BRG1 mutant non-small cell lung cancer, exploiting BRM dependency.
Collaboration with Lilly announced Dec 2021 includes US 50/50 co-development and co-commercialization.
Foghorn and Lilly plan to present preclinical data at upcoming scientific conferences.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.